Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Oncogenic FLT3 kinase is a clinically validated target in acute myeloid leukemia (AML), and both multi-targeted and selective FLT3 inhibitors have been developed. Spleen tyrosine kinase (SYK) has been shown to be activated and increased in FLT3-ITD-positive AML patients, and has further been shown t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Weisberg, Ellen L., Puissant, Alexandre, Stone, Richard, Sattler, Martin, Buhrlage, Sara J., Yang, Jing, Manley, Paul W., Meng, Chengcheng, Buonopane, Michael, Daley, John F., Lazo, Suzan, Wright, Renee, Weinstock, David M., Christie, Amanda L., Stegmaier, Kimberly, Griffin, James D.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581010/
https://ncbi.nlm.nih.gov/pubmed/28881711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados